Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.

Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, Slocum KL, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly ED, Straub C, Growney JD, Vander Heiden MG, Murphy AN, Pagliarini R, Metallo CM.

Cancer Res. 2014 Jun 15;74(12):3317-31. doi: 10.1158/0008-5472.CAN-14-0772-T. Epub 2014 Apr 22.

2.

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J.

Mol Cancer Ther. 2011 May;10(5):817-24. doi: 10.1158/1535-7163.MCT-10-0966. Epub 2011 Mar 7.

3.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.

PMID:
21258415
4.

The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.

McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, Jacks T.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3261-6. Epub 2007 Feb 20.

Supplemental Content

Loading ...
Support Center